Document is current
Any future updates will be listed below
-
Authors
Koester, Anja https://orcid.org/0009-0004-3142-9675
Witcher, Derrick R.
Lee, Mark
Demarest, Stephen J.
Potter, Scott
Werle, Katie
Bauer, Scott
Ruiz, Diana
Malherbe, Laurent
Poorbaugh, Josh
Glasebrook, Andrew
Preuss, Christoph https://orcid.org/0000-0003-1039-6080
Datta, Gourab
Wang, Ziqiao
Knorr, Jack
Manner, David
Patel, Dipak
Schmitz, Carsten
Klekotka, Paul
Nirula, Ajay
-
Funding
Funding for this research was provided by:
Eli Lilly and Company (N/A)
- License Information
-
More Information
Article History
Received: 6 November 2023
Accepted: 12 April 2025
First Online: 1 May 2025
Competing interests
: All authors with the exception of M.L. were employees, and many shareholders, of Eli Lilly and Company at the time of their initial work on this project, and declare no other competing interests. A.K., D.R.W., S.J.D., S.P., and D.R. hold a US patent (#11319370). M.L. is an investigator for AbbVie, Aclaris Therapeutics, Alfasigma, Almirall, Alumis, AnaptysBio, Arcutis Biotherapeutics, Arena Pharmaceuticals, Asana BioSciences, AstraZeneca, BELLUS Health, Boehringer Ingelheim, Brickell Biotech, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, Dermira, Eli Lilly and Company, Foamix Pharmaceuticals, Galderma, Incyte, Janssen, LEO Pharma, Pfizer, RAPT Therapeutics, Sun Pharma, and UCB.
